Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data
暂无分享,去创建一个
Li Wang | Yun Xiao | Fulong Yu | Yanyan Ping | Hongying Zhao | Yulan Deng | Xia Li | Yong Zhang | Chaohan Xu | Xia Li | Yun Xiao | Huihui Fan | Yanyan Ping | Chaohan Xu | Fulong Yu | Li Wang | Yulan Deng | Hongyi Zhang | Yong Zhang | Hongying Zhao | Hongyi Zhang | Huihui Fan
[1] A. G. de la Fuente. From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.
[2] D. Pe’er,et al. An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.
[3] R. Nahta,et al. P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. , 2013, Current medicinal chemistry.
[4] Xia Li,et al. Prioritizing cancer-related key miRNA–target interactions by integrative genomics , 2012, Nucleic acids research.
[5] Manu Setty,et al. Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma , 2012, Molecular systems biology.
[6] H. Katagiri,et al. ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis. , 2013, Anticancer research.
[7] Peter A. Jones,et al. Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.
[8] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[9] Bradley P. Coe,et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.
[10] Harald Martens,et al. Analysis of genetic marker-phenotype relationships by jack-knifed partial least squares regression (PLSR). , 2004, Hereditas.
[11] G. Pfeifer,et al. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. , 2010, Advances in genetics.
[12] Li Wang,et al. IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals. , 2014, Molecular bioSystems.
[13] J. Sarkaria,et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180 , 2014, Oncogene.
[14] Torbjörn E. M. Nordling,et al. Network modeling of the transcriptional effects of copy number aberrations in glioblastoma , 2011, Molecular systems biology.
[15] Marcel J. T. Reinders,et al. Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach , 2010, PLoS Comput. Biol..
[16] Tongbin Li,et al. miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..
[17] G. Hong,et al. Nucleic Acids Research , 2015, Nucleic Acids Research.
[18] Xin Chen,et al. TRANSFAC: an integrated system for gene expression regulation , 2000, Nucleic Acids Res..
[19] Jan Koster,et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.
[20] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[21] Eli Upfal,et al. De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.
[22] H. Kluger,et al. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies , 2012, Current Oncology Reports.
[23] J. Stockman,et al. A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .
[24] A. Bashashati,et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.
[25] M. Núñez,et al. Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. , 2013, Cancer letters.
[26] David L. Masica,et al. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. , 2011, Cancer research.
[27] Robert Tibshirani,et al. A network model of a cooperative genetic landscape in brain tumors. , 2009, JAMA.
[28] L. Deangelis,et al. Glioblastoma: molecular analysis and clinical implications. , 2013, Annual review of medicine.
[29] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[30] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[31] Shi-Hua Zhang,et al. Identifying multi-layer gene regulatory modules from multi-dimensional genomic data , 2012, Bioinform..
[32] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[33] Ivan Smirnov,et al. Clinical Stratification of Glioblastoma Based on Alterations in Retinoblastoma Tumor Suppressor Protein (RB1) and Association With the Proneural Subtype , 2012, Journal of neuropathology and experimental neurology.
[34] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[35] Paul A. Bates,et al. Global topological features of cancer proteins in the human interactome , 2006, Bioinform..
[36] Giovanni Tesoriere,et al. RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis , 2013, Journal of cellular physiology.
[37] Teresa M. Przytycka,et al. Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..
[38] M. Berger,et al. The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents , 2003, Molecular and Cellular Biology.
[39] Richard Simon,et al. Identifying cancer driver genes in tumor genome sequencing studies , 2011, Bioinform..
[40] Yun Xiao,et al. Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma. , 2013, Neuro-oncology.
[41] Nicholas T. Ingolia,et al. Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.
[42] Cathie Garnis,et al. Genetic alteration and gene expression modulation during cancer progression , 2004, Molecular Cancer.
[43] Mark D. Johnson,et al. Numb Regulates Glioma Stem Cell Fate and Growth by Altering Epidermal Growth Factor Receptor and Skp1‐Cullin‐F‐Box Ubiquitin Ligase Activity , 2012, Stem cells.
[44] A. Frigessi,et al. Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.
[45] L. Zender,et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles , 2014, Nature.
[46] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[47] D. Valle,et al. Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.
[48] E. Haralambieva,et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN&ggr;–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma , 2013, Journal of Cell Science.
[49] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[50] J. Gutkind,et al. A role for p38 MAPK in head and neck cancer cell growth and tumor‐induced angiogenesis and lymphangiogenesis , 2014, Molecular oncology.
[51] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[52] S. Chandna,et al. Connexin-43 regulates p38-mediated cell migration and invasion induced selectively in tumour cells by low doses of γ-radiation in an ERK-1/2-independent manner. , 2014, Carcinogenesis.
[53] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[54] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[55] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[56] S. Kellouche,et al. Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. , 2014, Experimental cell research.
[57] Roded Sharan,et al. Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..
[58] J. Olson,et al. p38 MAP kinase: a convergence point in cancer therapy. , 2004, Trends in molecular medicine.
[59] Shi-Hua Zhang,et al. Detecting disease associated modules and prioritizing active genes based on high throughput data , 2010, BMC Bioinformatics.
[60] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[61] R. Carpenter,et al. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3 , 2013, Molecular carcinogenesis.
[62] D. Gutmann,et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.
[63] C. Print,et al. Cell Cycle Gene Networks Are Associated with Melanoma Prognosis , 2012, PloS one.
[64] Bin Fang,et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms , 2013, Molecular systems biology.
[65] J. V. van Deursen,et al. Aneuploidy in health, disease, and aging , 2013, The Journal of cell biology.
[66] Peter Nürnberg,et al. Distinct methylation profiles of glioma subtypes , 2003, International journal of cancer.
[67] A. Lykkesfeldt,et al. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling , 2013, Breast Cancer Research and Treatment.
[68] K. Becker,et al. The Genetic Association Database , 2004, Nature Genetics.
[69] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..